Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate UpdateGlobeNewsWire • 07/23/20
Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 ManufacturingGlobeNewsWire • 07/07/20
Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional SharesGlobeNewsWire • 06/26/20
Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell DiseaseGlobeNewsWire • 06/12/20
Editas (EDIT) Up 10.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/06/20
Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell ImmunotherapiesGlobeNewsWire • 05/15/20
Editas Medicine, Inc. (EDIT) CEO Cynthia Collins on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20
Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor CancersGlobeNewsWire • 04/29/20
3 Stocks to Buy to Get a Big Bang for the Buck With Your Coronavirus Stimulus CheckThe Motley Fool • 04/15/20
Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock?Zacks Investment Research • 04/06/20
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/27/20
Why Biotech Stocks AnaptysBio, bluebird bio, and Editas Medicine Are Sinking TodayThe Motley Fool • 03/12/20